Roche Holding AG (XSWX:ROP) Moat Score: 8/10 (As of Jun. 27, 2026)


XSWX:ROP Roche Holding AG XSWX:ROP
77 GF Score
Price CHF336.00
GF Value CHF264.69
Valuation Modestly Overvalued
! 7 Warning Signs
View Full Analysis

What is Roche Holding AG Moat Score?

Roche Holding AG XSWX:ROP +0.21% 77 Moat Score is 8 as of Jun. 27, 2026. GuruFocus rates XSWX:ROP with a GF Score™ of 77/100 and a GF Value™ of CHF264.69 (Modestly Overvalued). The stock has 7 warning signs investors should review. Among 1,033 Drug Manufacturers companies, Roche Holding AG ranks better than 99.71% on this metric.

Roche Holding AG has the Moat Score of 8, which implies that the company might have Wide Moat - Clear and robust wide moat.

Roche Holding AG has Wide Moat: Roche Holding has a robust wide moat due to its strong market leadership in pharmaceuticals, extensive patent portfolio, and significant R&D capabilities. The company benefits from strong brand strength, regulatory barriers, and pricing power, ensuring durable competitive advantages.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Roche Holding AG might have Wide Moat - Clear and robust wide moat.

Roche Holding AG  (XSWX:ROP) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Roche Holding AG Moat Score Related Terms

XSWX:ROP vs LLY, JNJ, ABBV: Moat Score Comparison

For the Drug Manufacturers - General subindustry, Roche Holding AG's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Roche Holding AG Moat Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Roche Holding AG's Moat Score distribution charts can be found below:

* The bar in red indicates where Roche Holding AG's Moat Score falls into.


XSWX:ROP
77GF Score
Roche Holding AG XSWX:ROP
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 8 mean?
Roche Holding AG (XSWX:ROP) has a Moat Score of 8 as of Jun. 27, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Roche Holding AG ranks #3 out of 1033 companies in the Drug Manufacturers industry, placing it in the top 0.3%.
Is Roche Holding AG's Moat Score too high?
Roche Holding AG's current Moat Score is 8. Based on the distribution chart, Roche Holding AG ranks #3 out of 1033 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Roche Holding AG has a GF Score™ of 77/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Roche Holding AG's Moat Score compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Roche Holding AG ranks #3 out of 1033 companies for Moat Score. This places Roche Holding AG in the top 0% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Drug Manufacturers company?
A good Moat Score depends on the Drug Manufacturers industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Roche Holding AG's current Moat Score is 8. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Roche Holding AG stock overvalued right now?
Based on GuruFocus' analysis, Roche Holding AG (XSWX:ROP) is currently considered Modestly Overvalued. The stock's GF Value™ is CHF264.69, compared to a current price of CHF336.00 — trading 26.9% above its estimated fair value. The current Moat Score is 8. Roche Holding AG's overall GF Score™ is 77/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Roche Holding AG (XSWX:ROP), the current Moat Score is 8 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Roche Holding AG (XSWX:ROP) Overvalued in 2026?

Based on GuruFocus' analysis, Roche Holding AG stock appears to be overvalued. The current stock price of CHF336.00 is trading 26.9% above its estimated GF Value™ of CHF264.69. GuruFocus considers Roche Holding AG to be Modestly Overvalued.

Key valuation signals for XSWX:ROP:

  • Moat Score: 8
  • GF Value™: CHF264.69 vs. price of CHF336.00 (26.9% above fair value)
  • GF Score™: 77/100 with 7 warning signs

No single metric tells the full story. See the XSWX:ROP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Roche Holding AG Business Description

Address Grenzacherstrasse 124, Basel, CHE, 4070
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 40% of pharmaceutical sales, and centralized and point-of-care diagnostics for two-thirds of diagnostic-related sales.
77GF Score

Get the complete analysis for XSWX:ROP

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF336.00
Price
CHF264.69
GF Value